Cartesian Therapeutics Inc RNAC

$6.14 +0.25 (4.24%)

Valuation

Market cap
179,663,000
Revenue TTM
$2,800,000
Net income TTM
$-130,300,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-4,653.57%
Debt to equity
-0.42

Trading

Volume
279,900
Avg volume
152,054
Day's range
$5.89 – $6.32
Shares out
30,503,000
Stochastic %K
23%
Beta
0.74
Analysts
Strong Buy
Price target
$33.67

Price

Company profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia...

Show more

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Industry
Biotechnology
Sector
Healthcare
Phone
301 348 8698
Website
https://www.cartesiantherapeutics.com
Address
7495 New Horizon Way, Frederick, United States

Latest news

No headlines yet.